The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...

A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.

CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...

The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma has told Fierce Biotech, as the pharma continues to ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...